Immunotherapy for HCC: limitations in patients with NASH

Immunotherapy for HCC: limitations in patients with NASH

Bibliographic Details
Main Authors:	Parul D. Agarwal, Michael R. Lucey, Adnan Said, Jeremy Kratz
Format:	Article
Language:	English
Published:	Elsevier 2023-03-01
Series:	Annals of Hepatology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268122002289

Similar Items

Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
by: Yu S, et al.
Published: (2022-08-01)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
by: Paola Dongiovanni, et al.
Published: (2021-10-01)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
by: Miriam Longo, et al.
Published: (2021-04-01)

The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases
by: Daniela Gabbia, et al.
Published: (2021-06-01)

Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK
by: Chenxu Ge, et al.
Published: (2022-10-01)

HCC development is associated to peripheral insulin resistance in a mouse model of NASH.
by: Samuele De Minicis, et al.
Published: (2014-01-01)

Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)
by: Fuat Bicer, et al.
Published: (2023-11-01)

Unraveling the molecular links between benzopyrene exposure, NASH, and HCC: an integrated bioinformatics and experimental study
by: Zheming Yang, et al.
Published: (2023-11-01)

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
by: Hyunmi Kim, et al.
Published: (2021-04-01)

Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies
by: Jorge Gutiérrez-Cuevas, et al.
Published: (2022-12-01)

Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH.
by: Winston T Stauffer, et al.
Published: (2024-01-01)

Management of hepatocellular carcinoma recurrence after liver transplantation
by: Parul D. Agarwal, et al.
Published: (2022-01-01)

Hepatocellular carcinoma in a non-B non-C non-alcoholic steatohepatitis (NBNC-NASH HCC)
by: M. F., Fairudz, et al.
Published: (2010)

Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC
by: Yueqi Zhang, et al.
Published: (2021-05-01)

Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC
by: Vicent Ribas, et al.
Published: (2021-08-01)

FGF9 Recruits β‐Catenin to Increase Hepatic ECM Synthesis and Promote NASH‐Driven HCC
by: Lei Zhang, et al.
Published: (2023-10-01)

New techniques: a roadmap for the development of HCC immunotherapy
by: Dizhi Jiang, et al.
Published: (2023-06-01)

From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention
by: Benedetta Maria Motta, et al.
Published: (2023-11-01)

Butyrate limits inflammatory macrophage niche in NASH
by: Ankita Sarkar, et al.
Published: (2023-05-01)

Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review
by: Paola Muscolino, et al.
Published: (2023-08-01)

Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis
by: Henrik H. Hansen, et al.
Published: (2023-12-01)

Suppression of NASH-Related HCC by Farnesyltransferase Inhibitor through Inhibition of Inflammation and Hypoxia-Inducible Factor-1α Expression
by: Kohei Yamada, et al.
Published: (2023-07-01)

Tubulin Alpha 1b Is Associated with the Immune Cell Infiltration and the Response of HCC Patients to Immunotherapy
by: Xinyao Hu, et al.
Published: (2022-03-01)

Elucidating Cuproptosis-Associated Genes in the Progression from Nash to HCC Using Bulk and Single-Cell RNA Sequencing Analyses and Experimental Validation
by: Zizuo Zhao, et al.
Published: (2023-09-01)

Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC
by: Pierpaolo Biondetti, et al.
Published: (2021-11-01)

A novel cuproptosis-related prognostic signature and potential value in HCC immunotherapy
by: Xiang-Xu Wang, et al.
Published: (2022-09-01)

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
by: Yimin Zheng, et al.
Published: (2023-10-01)

Micro‐Engineered Organoid‐on‐a‐Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients
by: Zhengyu Zou, et al.
Published: (2023-09-01)

Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma
by: Utibe-Abasi S. Udoh, et al.
Published: (2022-07-01)

The Emerging Role of Metformin in the Treatment of Hepatocellular Carcinoma: Is There Any Value in Repurposing Metformin for HCC Immunotherapy?
by: Stavros P. Papadakos, et al.
Published: (2023-06-01)

DHX37 Is a Promising Prognostic Biomarker and a Therapeutic Target for Immunotherapy and Chemotherapy in HCC
by: Nanbin Liu, et al.
Published: (2023-10-01)

Nashe and satire
by: Stern, T
Published: (2017)

High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy
by: Angela Mauriello, et al.
Published: (2019-11-01)

Learning to Play Nash.
by: Foster, D, et al.
Published: (2000)

Surveillance for Hepatocellular Carcinoma in Patients with NASH
by: Philippe Kolly, et al.
Published: (2016-06-01)

Development of the Rabbit NASH Model Resembling Human NASH and Atherosclerosis
by: Momoko Hayashi, et al.
Published: (2023-01-01)

Nash Equilibrium and Bisimulation Invariance
by: Julian Gutierrez, et al.
Published: (2019-09-01)

High prevalence of periodontal disease in patients with NASH- possible association of poor dental health with NASH severity
by: Sven Pischke, et al.
Published: (2023-03-01)

Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression
by: Maria Kotsari, et al.
Published: (2023-07-01)

Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH)
by: Savneet Kaur, et al.
Published: (2019-10-01)